Background: High rates of reoperation following breast-conserving surgery (BCS) for positive margins are associated with costs to healthcare providers. The aim was to assess the quality of evidence on reported re-excision costs and compare the direct patient-level costs between patients undergoing successful BCS versus reoperations after BCS. 
Introduction
Breast cancer is the most common cancer among women in Europe, with 430 000 new cases diagnosed each year 1 . In England, approximately 55 000 patients are diagnosed annually 2 , the majority of whom are treated by breast-conserving surgery (BCS) 3 , followed by adjuvant radiotherapy 4 -9 . Definitive BCS is associated with similar survival rates to those achieved with mastectomy 10 . Unfortunately, on average, 18 per cent of patients with ductal carcinoma in situ (DCIS) and 27 per cent of those with invasive disease 3 undergoing BCS in the UK require reoperation for positive margins 11 . Positive margins after BCS are associated with a twofold increased risk of ipsilateral breast tumour recurrence, which is not negated by radiotherapy, systemic therapy or endocrine therapy 12 .
Reoperations after BCS lead to delay in delivery of adjuvant therapy 13 and potentially inferior cosmesis 14, 15 . Although not substantiated in the literature to date, this could also prompt patient anxiety and stress. Reoperations after breast surgery also represent a significant and as yet unestimated economic burden to the UK National Health Service (NHS). There are variations in treatment strategies after diagnosis of positive margins in Europe and, as an example, the Dutch national guidelines do not advocate re-excising focally positive margins following BCS and recommend whole-breast irradiation including boost 16, 17 . Although omission of re-excision may not affect 5-year disease-free and overall 10-year survival 16 , this approach is associated with higher rates of ipsilateral breast tumour recurrence and may be unacceptable to many patients 16 .
Although there have been a number of reports describing the cost burden associated with reoperations after breast surgery, there has been no attempt to review or synthesize this literature. Moreover, investigators have attempted to define the costs of reoperations after BCS using best estimates of patient charges 18, 19 or decision models that use hypothetical cohorts 20, 21 . Although there is an obvious cost burden to health systems, the idiosyncratic nature of costing methodologies used creates uncertainty around the magnitude and location of cost drivers across the BCS care pathway. Moreover, patient-level costs, derived from tracing expenditure incurred by resources at an individual-patient level have not been assessed for reoperations after BCS in the UK. Therefore, the aims of this study were to review and assess the quality of published evidence on the economic costs associated with reoperations after BCS; and to compare patient-level costs between women undergoing definitive BCS and those needing a reoperation after BCS, using Patient Level Information Costing Systems (PLICS).
Methods

Literature search
Database and search criteria
The electronic databases MEDLINE, Embase, Health Management Information Consortium (HMIC) and Scopus were queried from 1 January 2006 to 16 June 2017 in accordance with PRISMA guidelines 22 . Medical Subject Heading (MeSH) and all-field terms were used, adhering to the following search strategy.
The strategy for the first theme, breast cancer(s), was: ('Breast cancer (MeSH)' OR 'breast cancer$' OR 'breast tumour$' OR 'breast tumour$' OR 'mammary neoplasm$' OR 'mammary cancer$' OR 'breast carcinoma$') AND.
That for the second theme, interventions, was ('Margin$' OR 'cavity shave' OR 'lumpectomy$' OR 'partial mastectomy$') AND ('re-operation' OR 'readmission' OR 'recurrence' OR 'admission' OR 'reattendance' OR 'second operation' OR 'breast conserving surgery' OR 'length of stay') AND.
Economic outcomes was the third theme, with the search strategy: ('economic adj1 aspect' OR 'cost$3' OR 'health-care-cost$3' OR 'cost adj1 (analy$3 OR evaluation)' OR 'cost-effectiv$4' OR 'cost-benefit analy$3' OR 'cost-effectiv$4 analy$3' OR 'cost-utilit$2 analy$3' OR 'cost-utilit$2' OR 'cost-benefit' OR 'efficien$2' OR 'technical efficien$2' OR 'allocative efficien$2' OR 'financ$3 adj1 analy$3' OR 'financ$3 adj1 evaluation' OR 'productivity' OR 'organi#ational adj1 efficien$2' OR 'economic adj1 evaluation' OR 'economic adj endpoint').
Additional studies not captured by electronic searches were identified through bibliographic cross-referencing of included studies. Full articles were included if the primary reported outcome was per-patient cost of a reoperation for lumpectomy/BCS, or if raw data were available for independent calculation of this cost. Studies that reviewed intraoperative margin assessment (IMA) techniques as potential cost-saving strategies were included only if comparative reoperative costs without the technique in question were available (Fig. 1) . Costs are quoted in dollars; exchange rates used were US $1 = £0⋅75 and US $1 = €0⋅85 (exchange rate 21 April 2018).
Study quality assessment
Three investigators independently assessed methodological quality using the Quality of Health Economic Studies (QHES) instrument. This validated tool comprises 16 criteria that each consists of a point value ranging from 1 to 9 23 . A dichotomous (yes/no) response scale was used where a 'yes' attained all the allotted points and no zero points for that criterion. Papers were assigned an overall score ranging from 0 to 100 (Tables S1-S4 , supporting information). Discrepancies in QHES score, defined arbitrarily as a variation of more than 10 points between two assessors, occurred for only one paper, and were resolved by discussion with the third assessor until consensus was achieved. Abstracted economic data comprised: initial BCS costs, reoperative BCS costs, type of economic analysis, perspective, care pathway focus and source of cost estimates.
Where a clear margin was recorded as 'no ink on tumour' in the specimen histopathology report, a margin distance of 0 mm was used. Positive margin and reoperation rates were reported to one decimal place. All costs were described in the original currency provided by each study, rounded to the nearest whole figure. Where costs were described as a range, the mean value was used as the cost estimate. If costs were reported with and without an IMA technique, the cost without an IMA technique was used. Costs of radiotherapy were included where available.
Access, clinical data registry and patient-level financial databases
This study was registered under Service Evaluation Registration at Imperial College Healthcare NHS Trust (registration identification number 146). The Somerset Cancer Register (Somerset Health Informatics Service, Somerset, UK), a national electronic health record designed to coordinate and improve cancer care, was used to identify and extract source data, including: patient-level data, and demographic, clinical, procedural and histopathology information (Fig. 2) 
Clinical outcome data
The type of index BCS was recorded and included either wide local excision, or therapeutic mammoplasty with no axillary procedure (for example in patients with DCIS), sentinel node biopsy or axillary lymph node dissection. In accordance with hospital standards, if a patient was identified as having positive margins (disease at inked margin) or close margins (defined as less than 2 mm) on initial BCS, reoperation was performed; this constituted either further margin re-excision, or mastectomy with or without reconstruction, along with appropriate local nodal treatment (surgery or radiotherapy). Each patient was tracked until clear margins were obtained. Clinicopathological variables including histopathological subtype, presence of high-grade invasive disease, presence of lymph node metastasis, oestrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, margin status and margin shaves were also recorded. Receipt of adjuvant or neoadjuvant therapies, including chemotherapy, radiotherapy and endocrine therapy, was identified. Co-morbidity was assessed using the Charlson Co-morbidity Index (CCI), a validated weighted index that estimates mortality risk from co-morbid disease 24 . 
Financial outcome data
Total costs relating to BCS and subsequent reoperations were obtained for inpatient episodes only. Direct medical costs included: consultant, nursing and other health professionals' time, use of pharmaceutical products, and diagnostic and interventional procedure costs including consumables. Direct non-medical costs were captured as capital overhead costs. Operating theatre time (in minutes) and length of hospital stay (in days) were recorded. Costs are expressed in British pounds and rounded to the nearest integer. The exchange rate used here was £1 = €1⋅14 (exchange rate 21 April 2018). The primary outcome of this study was the total cost of BCS with or without reoperation(s). Exploratory outcomes were demographic, clinical, procedural and histopathological characteristics that predict the total cost of BCS.
Estimating total costs and breast-conserving surgery cost drivers
Total costs for each CCI risk group (low risk, CCI score less than 2; high risk, CCI score 2 or more) and reoperation status (initial BCS, 1 reoperation or 2 reoperations) were derived to calculate the distributions of total costs. To explore the drivers of total cost, demographic, clinical, procedural and histopathological information (independent variable) were regressed on total costs (dependent variable) to examine causal relationships between independent variables and total costs. Pathological interactions explored were: presence of invasive and/or non-invasive disease. Therapeutic variables explored included: chemotherapy, radiotherapy, neoadjuvant chemotherapy, endocrine therapy and combinations of all therapies.
Statistical analysis
Normality tests were performed to estimate the appropriateness of parametric estimators, and inferential statistics were employed according to these assumptions. Associations between categorical variables (age, CCI, clinicopathological variables and adjuvant therapies) and reoperations were examined using χ 2 tests for linear trends. Associations between direct costs of BCS and subsequent reoperation(s) were examined using Mann-Whitney U and Kruskal-Wallis tests. Propensity score matching was applied as an alternative to the use of CCI risk groups to control for a wider array of unobserved and observed confounders. Homogeneous patient groups were compared by ANOVA, and multivariable linear regression (ordinary least squares, OLS) was used to test the direction and magnitude of associations between patient descriptors (age, CCI, clinicopathological features and receipt of adjuvant therapies) and total care costs. Statistically significant differences between groups were defined at the 5 per cent level. Statistical analysis was conducted using Stata ® version 14.2 (StataCorp, College Station, Texas, USA).
Results
Health economic review and quality assessment
Electronic literature searches identified a total of nine papers 18 -21,25-29 for in-depth assessment (Fig. 1) . The median QHES score was 47 (i.q.r. 32⋅5-79). Two studies scored in the upper quartile (score over 75), and one in the lower quartile (less than 25). The majority of studies (6 of 9) were from North America, two were from Europe and one was from Asia (Table S2 , supporting information). Four studies examined hospital records retrospectively, and two recorded patient information prospectively for a specified time after admission. All studies used a cost-benefit analysis and focused on the perioperative phase. Two studies 20, 21 used a prediction model, whereby a decision-tree analysis was undertaken to model the cost impact of re-excision following BCS. Only direct medical costs were reported; indirect costs (not directly accountable to the operation) and intangible costs (unquantifiable cost relating to an identifiable source) were not estimated in any of the reviewed literature. (Fig. S1 , supporting information). Demographic factors including age and CCI were not associated with reoperation ( Table 1) . The need for reoperation was not associated with receipt of therapies including neoadjuvant chemotherapy, adjuvant chemotherapy, adjuvant radiotherapy or endocrine therapy ( Table 2 ). Lymph node status was significantly associated with reoperation (P = 0⋅043), but tumour grade, ER, PR and HER2 status were not ( Table 3) ; this may be due in part to the small sample size. Ten patients were recorded as having undergone margin shaves during the initial BCS operation; none of those undergoing reoperation had a margin shave performed at index surgery. Of the 59 patients undergoing reoperation, 13 procedures (22 per cent) were for invasive disease, 22 (37 per cent) for non-invasive disease, and 24 (41 per cent) for mixed invasive and non-invasive disease (Table S5 , supporting information). Of 13 patients who had reoperation for invasive disease, the margins were 0 mm or ink on tumour in two patients, between 0⋅1 and 0⋅99 mm in seven, and between 1 and 1⋅99 mm from the inked radial margin in four. Of 22 patients who had reoperation for non-invasive disease, ten had disease present at ink (0 mm), ten had margin widths of 0⋅1-0⋅99 mm and two had margin widths of 1-1⋅99 mm. All second reoperations were performed for margins of 0-1 mm for either invasive or non-invasive disease (Table S6 , supporting information). Reoperation included 50 margin or cavity re-excisions and one mammoplasty. Second reoperation(s) included four further wide excisions, three mastectomies without immediate reconstruction and one mastectomy with immediate reconstruction (Fig. S1 , supporting information).
Financial outcomes
Patient-level costs associated with definitive BCS versus reoperative breast surgery are summarized in The overall cost of definitive BCS and one reoperation (51 patients) was £360 474, with a median cost of £4408 (2847-6672; 1752-28 705) per patient. Compared with the cost of definitive BCS, the additional cost of one reoperation (£2033) was statistically significant (P < 0⋅001). The median total theatre time of BCS and one reoperation was 165 (136-256; 77-892) min and the total theatre cost was £1054 (691-1775; 328-8385).
The overall cost of BCS and two reoperations (8 patients) was £59 811, with a median cost of £8182 (5924-10 006; 5895-18 019) per patient. Two reoperations cost an additional £3774 compared with only one reoperation (P < 0⋅001) (Fig. 3) . The median total theatre time for BCS and two reoperations was 361 (257-369; 217-396) min and the total median theatre cost was £2483 (1690-2722; 1467-3042). Overall, the median cost of BCS and any reoperation (59 patients) was £4511 (2914-7123; range 1752-18 019), which represented a significant additional cost of £2136 per patient compared with the median cost of £2375 for definitive BCS (153 patients) (P < 0⋅001).
Causal estimates relating to cost drivers
The results of linear OLS regression indicated that the number of reoperations was the most important predictor of total costs in BCS (coefficient = £4919, P < 0⋅001) (Table S7 , supporting information). The reoperation rate at the authors' institution during the episode of review was 27⋅8 per cent, corresponding to an additional cost of £139 213 per annum. A deterministic sensitivity analysis was conducted to extrapolate costs based on different hypothesized rates of re-excision given the heterogeneity of clinical outcomes in other institutions (Fig. S2, supporting  information) .
The presence of nodal metastasis was associated with higher total costs (+£2093; P = 0⋅003), and receipt of radiotherapy with a relative cost attenuation (-£2373; P = 0⋅002). The presence of nodal metastasis was a strong positive predictor of the number of reoperations (P < 0⋅001), whereas receipt of adjuvant radiotherapy was a strong negative predictor (P < 0⋅001). Given the non-randomized nature of this study, co-variables used for propensity score matching have the potential to causally explain marginal costs related to reoperation rates (Table S8 , supporting information). Construction of propensity scores offsets challenges caused by non-randomized designs and enables causal relationships between a dependent variable (total costs) and various explanatory independent variables (co-variables) to be inferred. Propensity score matching analysis confirmed that number of reoperations (+£5708; P < 0⋅001) and receipt of radiotherapy (-£4684; P < 0⋅001) were associated with total costs.
Further analysis revealed that median costs for five patients in whom BCS failed, prompting mastectomy with immediate reconstruction (4 deep inferior epigastric perforator flap, 1 implant reconstruction) but without radiotherapy, were significantly greater than those of definitive BCS with subsequent radiotherapy (124 patients): median £22 501 (i.q.r. £9151; range 10 979-28 705) and £2446 (1647; 923-8260) respectively (P < 0⋅001). Moreover, after exclusion of patients who underwent BCS with reoperation and immediate reconstruction, supplementary propensity score matching and OLS analysis showed no negative effect of radiotherapy on costs (propensity score matching: P = 0⋅326; OLS: P = 0⋅488). Although the presence of nodal metastasis was not an independent predictor of costs per se, nodal metastasis was a strong predictor of reoperation and hence may have exerted an indirect effect on costs.
Discussion
It is imperative to systematically assess and describe the quality of studies in the field of reoperations after breast surgery to ensure that value-based assessments are made using comprehensive and robust data. As healthcare expenditure on cancer in the UK continues to increase annually, pressure rises to contain spending and optimize costs. Payers, care providers and regulatory bodies are increasingly using economic evaluations to improve care quality across populations 23 .
The present health economic review highlights the heterogeneity and paucity of high-quality studies reporting cost estimates of reoperations in breast surgery. Only nine studies 18 -21,25-29 have commented on reported costs of re-excision in BCS, with two 20,21 employing a predictive model to hypothesize the cost impact of re-excision following BCS in the USA and Canada. Several studies contained minimal cost information, whereas others reported a range of costs for numerous variables that could not be collated accurately. The present analysis revealed that less than one-quarter of economic analyses in reoperative breast surgery are of high quality (score at least 75), as defined by the QHES instrument. The validity of economic models that adopt a health system perspective depends on the structural assumptions used to approximate clinical reality 30 . The lack of methodological detail informing these assumptions in the reviewed literature makes it difficult for readers to ascertain to what extent these cost estimates can be applied in clinical practice.
A framework was constructed to interrogate the associated costs of the entire care pathway after the index BCS operation. Combining registry and patient-level costing enabled a novel and granular analysis of individual-patient pathway costs of reoperations after breast surgery from admission to discharge. This study thus allows a comparison between definitive BCS and reoperations in the UK, interrogating direct patient-level costs including those associated with the operating theatre, medical staffing and laboratory investigations.
PLICS represents a relatively new approach to costing care in the NHS. It changes the way in which costs of frontline care activity are assessed, providing better itemization of the care delivered to NHS patients. PLICS software allows more accurate cost information at each stage of the patient's journey and reflects the causality of costs in the BCS pathway, tracing which type of activity is incurring cost for each patient. Before the introduction of PLICS in the NHS, the principal source of costing data was reference costs 31 . However, there were several concerns with reference costs, including the collation of cost based on healthcare resource group averages, so that information relating to underlying diagnoses or operative procedures was not included 32 . The guidance informing reference cost collection can also be interpreted variably, complicating meaningful comparison across Trusts. As an alternative, patient-level costing has heralded a shift in hospital costing methodology from a mainly top-down approach of cost allocation to a more direct approach, whereby every effort is made to cost all interventions and events that could be associated with individual patients 32 .
Here, reoperations after BCS added significantly to patient-level healthcare costs. Specifically, reoperations added on average £2136 per patient compared with definitive excision at index BCS. It is acknowledged that the re-excision rate (27⋅8 per cent) for non-invasive and invasive disease in the present study is at the upper end of published re-excision rates (ranging from 20⋅3 to 29⋅7 per cent) 3 . Applying these empirical cost estimates to national data, however, provides compelling evidence for interventions to curtail reoperations in breast surgery, reduce associated costs and redirect resources elsewhere. For example, Jeevan and colleagues 3 identified that 55 297 women had at least one breast reoperation between April 2005 and March 2008, which, based on the present patient-level estimates of additional costs, results in an extrapolated total triennial cost burden of £118 million to the NHS. This further highlights the importance of getting breast conservation right first time. Indeed, there may be potential to better estimate the actual cost saving to the UK NHS in reducing reoperations in BCS through the Getting It Right First Time (GIRFT) initiative 33 . This may prompt initiatives to improve preoperative and intraoperative decision-making, curtail unwarranted practice variations, and bring about efficiencies to be ploughed back into services. Conversely, a more liberal approach to reducing costs could be adopted in line with the Dutch national guidelines, which omit re-excision for focally positive margins, and recommend using whole-breast radiotherapy including boost. However, this has been associated with an increased risk of ipsilateral breast tumour recurrence (2⋅9 versus 1⋅1 per cent at 5 years) 17 , which may lead to added costs in the long-term. Another approach is to employ tissue characterization technologies or IMA to enable better intraoperative decisions and drive down positive margin rates. Established IMA techniques include frozen-section analysis, cytology, intraoperative ultrasonography and specimen radiography, all of which have unique limitations; no single IMA technique has gained universal adoption to date 34 . Emerging technologies such as MarginProbe ® (DUNE Medical Devices, Alpharetta, Georgia, USA) 35 have been found to reduce reoperation rates to 14⋅1 per cent. The iKnife (Waters Corporation, Milford, Massachusetts, USA), is a novel mass spectrometric method that allows intraoperative analysis of breast tissue types and thus resection margin status in vivo by interpretation of cellular chemical components. Despite good sensitivity (94⋅1 per cent), the iKnife was noted to have modest specificity (87⋅3 per cent) in analysing solid benign lesions (fibroadenoma) compared with tumour in a subset analysis 36 . Moreover, adoption is potentially hampered by device costs, associated consumables and maintenance costs. Notably, at the authors' institution, the Faxitron ® BioVision (Faxitron Bioptics, Tucson, Arizona, USA), a biopsy specimen imaging system, costs approximately £75 000 for single purchase with annual service costs of approximately £6000. However, a limitation of this estimate is that procurements can vary substantially between NHS providers as evidenced by the Carter Review in 2016 37 . This is also consistent with well cited ambiguities between list prices and discounts for medical products 38 .
An alternative more frugal approach is to adopt routine cavity shave, a procedure in which each edge of the index cavity is systematically and indiscriminately shaved to create a thin piece of tissue for further histological analysis. A recent RCT 39 suggested that routine cavity shaves halved the positive margin rate and subsequent re-excision rate among patients undergoing BCS, despite a mean volume loss differential of 36⋅1 cm 3 . Few studies have, however, evaluated the effect of shaved margins on cosmesis. This is critical because economic gains as a result of routine cavity shaves may be offset if greater volume loss leads to costly reconstructive procedures to correct cosmetic deficits at a later date.
Limitations of this study include a relatively small sample size, and heterogeneity and inconsistency in the application of patient-level costs within the authors' Trust. Nevertheless, the introduction of healthcare costing standards for England developed by the Healthcare Financial Management Association (HFMA) has provided a nationalized standardized framework that specifies how patient-level costs should be tracked, managed and reported. Through the HFMA, organizations are encouraged to report on the quality of their current costing process and focus attention on areas that require improvement, providing a central validation process for the costs 31 . Moreover, research by the Nuffield Trust 32 supports the use of PLICS to generate cost savings and reduce waste. PLICS are also being continually developed by NHS Improvement, under a programme called the Care Transformation Programme, allowing more attention and resource to validating the data captured 40 . Here, an assumption was made that national tariffs, which are often used to derive 'costs' in economic analyses, are less appropriate for detailed cost analyses because the methodology by which these prices are set leads to bundling of several resource items using data from hundreds of NHS Trusts. The cost of multidisciplinary team discussion and administration, and admission scheduling has not yet been reported in the literature. Similarly, indirect and intangible costs, such as those associated with leave of absence, work productivity loss and emotional distress, have been captured inadequately, but should be considered in order to provide comprehensive economic estimates. Indeed, to date, only one study 41 has estimated indirect costs (US $8236) associated with breast cancer in women aged 50-64 years.
There are compelling reasons to reduce the rate of positive margins and reoperative breast surgery to negate the risk of ipsilateral breast tumour recurrence, including inferior cosmesis and delayed adjuvant therapies. This study has demonstrated the magnitude of added patient-level costs of reoperations after BCS, established a framework for further health economic analyses, and provided substantial economic justification to implement IMA technologies to reduce the rate of positive margins and maximize the chances of successful index BCS.
